ArticleNature medicine2020
Lopinavir-ritonavir in severe COVID-19.
Article in Nature medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 58 citations in OpenAlex.
- Plausible mechanism of drug resistance and side-effects of COVID-19 therapeutics: a bottleneck for its eradication.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2024Review
- Article
- Evaluation of clinical and laboratory characteristics and factors affecting mortality in 500 hospitalized COVID-19 patients: A retrospective study.Saudi medical journal · 2022Article
- Impact of Liver Functions by Repurposed Drugs for COVID-19 Treatment.Journal of clinical and translational hepatology · 2022Review
- Effects of Drugs Formerly Proposed for COVID-19 Treatment on Connexin43 Hemichannels.International journal of molecular sciences · 2022Article
- Significance of Immune Status of SARS-CoV-2 Infected Patients in Determining the Efficacy of Therapeutic Interventions.Journal of personalized medicine · 2022Review
- Functional food: complementary to fight against COVID-19.Beni-Suef University journal of basic and applied sciences · 2022Review
- Drug-induced liver injury in COVID-19 treatment: Incidence, mechanisms and clinical management.Frontiers in pharmacology · 2022Review
- Convalescent plasma therapy in COVID-19 patients: a non-randomized case-control study with concurrent control.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2022Article
- Cellular miR-150-5p may have a crucial role to play in the biology of SARS-CoV-2 infection by regulatingRNA biology · 2022Article
- Discovery of juglone and its derivatives as potent SARS-CoV-2 main proteinase inhibitors.European journal of medicinal chemistry · 2021Article
- Bayesian neural network with pretrained protein embedding enhances prediction accuracy of drug-protein interaction.Bioinformatics (Oxford, England) · 2021Article
- Exploring the interaction of quercetin-3-O-sophoroside with SARS-CoV-2 main proteins by theoretical studies: A probable prelude to control some variants of coronavirus including Delta.Arabian journal of chemistry · 2021Article
- Review
- Rifampicin and Letermovir as potential repurposed drug candidate for COVID-19 treatment: insights from an in-silico study.Pharmacological reports : PR · 2021Article
- COVID-19 infection and rheumatoid arthritis: mutual outburst cytokines and remedies.Current medical research and opinion · 2021Review
- Biomedical Text Link Prediction for Drug Discovery: A Case Study with COVID-19.Pharmaceutics · 2021Article
- Role of phytoconstituents in the management of COVID-19.Chemico-biological interactions · 2021Review
- Therapeutic Potential of EGCG, a Green Tea Polyphenol, for Treatment of Coronavirus Diseases.Life (Basel, Switzerland) · 2021Article
- Article
Corrections and comments
- Comment on
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.